Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	Vandetanib	47
Overall Study	STARTED	Placebo	48
Overall Study	Assessable Set : Primary Analysis	Vandetanib	44
Overall Study	Assessable Set : Primary Analysis	Placebo	45
Overall Study	Secondary Analysis Set	Vandetanib	47
Overall Study	Secondary Analysis Set	Placebo	48
Overall Study	Safety Analysis Set	Vandetanib	48
Overall Study	Safety Analysis Set	Placebo	47
Overall Study	COMPLETED	Vandetanib	33
Overall Study	COMPLETED	Placebo	40
Overall Study	NOT COMPLETED	Vandetanib	14
Overall Study	NOT COMPLETED	Placebo	8

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00659438/flow